Literature DB >> 7768621

Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

M R Fontana1, R Manetti, V Giannelli, C Magagnoli, A Marchini, R Olivieri, M Domenighini, R Rappuoli, M Pizza.   

Abstract

Using computer modelling, we have identified some of the residues of the A subunit of cholera toxin (CT) and heat-labile toxin that are involved in NAD binding, catalysis, and toxicity. Here we describe the site-directed mutagenesis of the CT gene and the construction of CT mutants. Nine mutations of the A subunit gene were generated. Six of them encoded proteins that were fully assembled in the AB5 structure and were nontoxic; these proteins were CT-D53 (Val-53-->Asp), CT-K63 (Ser-63-->Lys), CT-K97 (Val-97-->Lys), CT-K104 (Tyr-104-->Lys), CT-S106 (Pro-106-->Ser), and the double mutant CT-D53/K63 (Val-53-->Asp, Ser-63-->Lys). Two of the mutations encoded proteins that were assembled into the AB5 structure but were still toxic; these proteins were CT-H54 (Arg-54-->His) and CT-N107 (His-107-->Asn). Finally, one of the mutant proteins, CT-E114 (Ser-114-->Glu), was unable to assemble the A and the B subunits and produced only the B oligomer. The six nontoxic mutants were purified from the culture supernatants of recombinant Vibrio cholerae strains and further characterized. The CT-K63 mutant, which was the most efficient in assembly of the AB5 structure, was used to immunize rabbits and was shown to be able to induce neutralizing antibodies against both the A and B subunits. This molecule may be useful for the construction of improved vaccines against cholera.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768621      PMCID: PMC173311          DOI: 10.1128/iai.63.6.2356-2360.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  An oral B subunit: whole cell vaccine against cholera.

Authors:  J Holmgren; A M Svennerholm; M Jertborn; J Clemens; D A Sack; R Salenstedt; H Wigzell
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

Authors:  H Peltola; A Siitonen; H Kyrönseppä; I Simula; L Mattila; P Oksanen; M J Kataja; M Cadoz
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

3.  Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.

Authors:  W N Burnette; V L Mar; B W Platler; J D Schlotterbeck; M D McGinley; K S Stoney; M F Rohde; H R Kaslow
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

4.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

5.  Outbreak of Vibrio cholerae non-O1 in India and Bangladesh.

Authors:  M K Bhattacharya; S K Bhattacharya; S Garg; P K Saha; D Dutta; G B Nair; B C Deb; K P Das
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

Review 6.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.

Authors:  B D Spangler
Journal:  Microbiol Rev       Date:  1992-12

7.  Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli.

Authors:  T K Sixma; S E Pronk; K H Kalk; E S Wartna; B A van Zanten; B Witholt; W G Hol
Journal:  Nature       Date:  1991-05-30       Impact factor: 49.962

8.  Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity.

Authors:  T Tsuji; T Inoue; A Miyama; M Noda
Journal:  FEBS Lett       Date:  1991-10-21       Impact factor: 4.124

9.  Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin.

Authors:  Y Lobet; C W Cluff; W Cieplak
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin.

Authors:  T K Sixma; K H Kalk; B A van Zanten; Z Dauter; J Kingma; B Witholt; W G Hol
Journal:  J Mol Biol       Date:  1993-04-05       Impact factor: 5.469

View more
  25 in total

1.  Cholera toxin toxicity does not require functional Arf6- and dynamin-dependent endocytic pathways.

Authors:  Ramiro H Massol; Jakob E Larsen; Yukako Fujinaga; Wayne I Lencer; Tomas Kirchhausen
Journal:  Mol Biol Cell       Date:  2004-05-14       Impact factor: 4.138

2.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

3.  Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.

Authors:  C Magagnoli; R Manetti; M R Fontana; V Giannelli; M M Giuliani; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

5.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.

Authors:  Yongjun Sui; George K Lewis; Yichuan Wang; Kurt Berckmueller; Blake Frey; Amiran Dzutsev; Diego Vargas-Inchaustegui; Venkatramanan Mohanram; Thomas Musich; Xiaoying Shen; Anthony DeVico; Timothy Fouts; David Venzon; James Kirk; Robert C Waters; James Talton; Dennis Klinman; John Clements; Georgia D Tomaras; Genoveffa Franchini; Marjorie Robert-Guroff; Giorgio Trinchieri; Robert C Gallo; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

8.  Probing the endocytic pathway in live cells using dual-color fluorescence cross-correlation analysis.

Authors:  Kirsten Bacia; Irina V Majoul; Petra Schwille
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

9.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

10.  A nontoxic cholera enterotoxin (CT) analog is chimeric with regard to both epitypes of CT-B subunits, CT-B-1 and CT-B-2.

Authors:  M Boesman-Finkelstein; J W Peterson; L S Thai; R A Finkelstein
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.